{"id":8045,"date":"2023-11-01T16:57:26","date_gmt":"2023-11-01T08:57:26","guid":{"rendered":"https:\/\/clinicalvalue.com\/hcc-monitoring-and-surveillance-update-the-limbic\/"},"modified":"2024-02-26T21:31:56","modified_gmt":"2024-02-26T13:31:56","slug":"hcc-monitoring-and-surveillance-update-the-limbic","status":"publish","type":"post","link":"https:\/\/clinicalvalue.com\/en-au\/hcc-monitoring-and-surveillance-update-the-limbic\/","title":{"rendered":"HCC Monitoring and Surveillance Update &#8211; The Limbic"},"content":{"rendered":"<p>[vc_row][vc_column][vc_single_image image=&#8221;7560&#8243; img_size=&#8221;1920&#215;1073&#8243;][vc_column_text]In these series of videos produced by the limbic, A\/Prof. Simone Strasser and A\/Prof. Jessica Howell discuss:<\/p>\n<ul>\n<li>how changes in the epidemiology of advanced liver disease \u2013 both in Australia and globally \u2013 present challenges to the surveillance and monitoring of hepatocellular carcinoma<\/li>\n<li>discuss ways that specialists can ensure at-risk patients are undergoing surveillance for HCC<\/li>\n<li>current and future approaches to HCC surveillance and monitoring<\/li>\n<\/ul>\n<p style=\"text-align: center;\">Watch the videos below:<\/p>\n<p>[\/vc_column_text][vc_separator][vc_column_text]<\/p>\n<h2 style=\"text-align: center;\">The changing epidemiology of advanced liver disease and HCC<\/h2>\n<p>[\/vc_column_text][vc_video link=&#8221;https:\/\/player.vimeo.com\/video\/862986606&#8243; el_width=&#8221;80&#8243; align=&#8221;center&#8221;][vc_separator][vc_column_text]<\/p>\n<h2 style=\"text-align: center;\">HCC surveillance in at-risk patients<\/h2>\n<p>[\/vc_column_text][vc_video link=&#8221;https:\/\/player.vimeo.com\/video\/861874214?h=d10a7213be&#8221; el_width=&#8221;80&#8243; align=&#8221;center&#8221;][vc_separator][vc_column_text]<\/p>\n<h2 style=\"text-align: center;\">Limitations of current HCC surveillance strategies and future solutions<\/h2>\n<p>[\/vc_column_text][vc_video link=&#8221;https:\/\/player.vimeo.com\/video\/862988564?h=36d13c5219&#8243; el_width=&#8221;80&#8243; align=&#8221;center&#8221;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_single_image image=&#8221;7560&#8243; img_size=&#8221;1920&#215;1073&#8243;][vc_column_text]In these series of videos produced by the limbic, A\/Prof. Simone Strasser and A\/Prof. Jessica Howell discuss: how changes in the epidemiology of advanced liver disease \u2013 both in Australia and globally \u2013 present challenges to the surveillance and monitoring of hepatocellular carcinoma discuss ways that specialists can ensure at-risk patients are undergoing surveillance for HCC current and&#8230;<\/p>\n","protected":false},"author":12,"featured_media":7911,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1285],"tags":[1301,1302],"cancer-type":[1296],"country":[1268],"class_list":["post-8045","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-expert-opinions-en-au","tag-hcc-en-au","tag-surveillance-en-au","cancer-type-liver-en-au","country-au"],"jetpack_featured_media_url":"https:\/\/clinicalvalue.com\/app\/uploads\/2023\/11\/HCC-monitoring-and-surveillance-udpate.png","_links":{"self":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts\/8045"}],"collection":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/comments?post=8045"}],"version-history":[{"count":7,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts\/8045\/revisions"}],"predecessor-version":[{"id":8052,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/posts\/8045\/revisions\/8052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/media\/7911"}],"wp:attachment":[{"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/media?parent=8045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/categories?post=8045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/tags?post=8045"},{"taxonomy":"cancer-type","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/cancer-type?post=8045"},{"taxonomy":"country","embeddable":true,"href":"https:\/\/clinicalvalue.com\/en-au\/wp-json\/wp\/v2\/country?post=8045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}